Proliferative diabetic retinopathy: laser or eye injection?

The Lancet

Volumn 389, Issue 10085, 2017, Pages 2165-2166

  Ting, Daniel Shu Wei ^a,b   Wong, Tien Yin ^a,b  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; FUSION PROTEIN; VASCULOTROPIN RECEPTOR;

BEST CORRECTED VISUAL ACUITY; BINDING AFFINITY; CLINICAL OUTCOME; COLOR VISION; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE SEVERITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; LASER; LASER COAGULATION; NOTE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RETINA DETACHMENT; RETINA ISCHEMIA; VISUAL FIELD; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE; WET MACULAR DEGENERATION; DIABETIC RETINOPATHY; TREATMENT OUTCOME; VISUAL ACUITY;

DIABETIC RETINOPATHY; HUMANS; LASER COAGULATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85018401266     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31194-7     Document Type: Note

References (12)

1. Ting, DS, Cheung, GC, Wong, TY, Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 44 (2016), 260–776.
2. Cheung, N, Mitchell, P, Wong, TY, Diabetic retinopathy. Lancet 376 (2010), 124–136.
3. Yau, JW, Rogers, SL, Kawasaki, R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35 (2012), 556–564.
4. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85 (1978), 82–106.
5. Wong, TY, Mwamburi, M, Klein, R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32 (2009), 2307–2313.
6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 88 (1981), 583–600.
7. Gross, JG, Glassman, AR, Jampol, LM, et al., for the Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314 (2015), 2137–2146.
8. Aiello, LP, Avery, RL, Arrigg, PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994), 1480–1487.
9. Simunovic, MP, Maberley, DA, Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis. Retina 35 (2015), 1931–1942.
10. Sivaprasad, S, Prevost, AT, Vasconcelos, JC, et al., on behalf of the CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet, 2017 published online May 7 http://dx.doi.org/10.1016/S0140-6736(17)31193-5.
11. Weidle, UH, Schneider, B, Georges, G, Brinkmann, U, Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 9 (2012), 357–372.
12. Holz, FG, Tadayoni, R, Beatty, S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99 (2015), 220–226.